The Shares Researcher

Intro I have to warn you. Compared to almost all other companies mentioned on this blog, Agios is not generating any meaningful cash flow at the moment and, as you may have guessed, is in the “risky” biopharmaceutical business. Do I have any special knowledge in this sector? No. So why bother? Without going into any details in terms of their products or clinical pipeline which consists of programs in alpha- and beta-thalassemia or sickle cell disease where I certainly cannot add any value, I will try to focus on what I better understand: its financial position. At the end of 2020, Agios sold its oncology business for up to $2 billion plus royalties. The proceeds will and have been used to advance its pipeline and to buy back roughly $1.2 billion worth of its own shares.   Valuation At the end of March 2022, Agios had cash and marketable securities worth almost $1.2 billion and pretty much no financial liabilities. There are currently 71 million shares outstanding which ...